Verastem Inc. (VSTM)

4.33
NASDAQ : Health Technology
Prev Close 4.33
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.78 / 5.71
Avg Volume 793.70K
Exchange NASDAQ
Shares Outstanding 50.97M
Market Cap 219.16M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Verastem Updates Presentation Time For Oppenheimer & Co. Healthcare Conference

Verastem Updates Presentation Time For Oppenheimer & Co. Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 28th Annual Oppenheimer...

Verastem To Present At Upcoming Conferences

Verastem To Present At Upcoming Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following investor...

Verastem Reports Year-End 2017 Financial Results

Verastem Reports Year-End 2017 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the year ended December 31, 2017 and...

Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to eight new employees to purchase an...

Verastem To Present At The 30th Annual ROTH Conference

Verastem To Present At The 30th Annual ROTH Conference

Verastem, Inc. (NASDAQ:VSTM), focused on developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 30 th Annual ROTH Conference on Monday, March...

Verastem Submits New Drug Application To U.S. FDA For Duvelisib For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma And Follicular Lymphoma

Verastem Submits New Drug Application To U.S. FDA For Duvelisib For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma And Follicular Lymphoma

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced it has submitted a New Drug Application (NDA) to the U.

Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to six new employees to purchase an...

Verastem Presents Preclinical Data At ASCO-SITC Highlighting The Synergistic Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

Verastem Presents Preclinical Data At ASCO-SITC Highlighting The Synergistic Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that a poster highlighting the synergistic effects of duvelisib in...

Verastem Announces Increased Hercules Debt Facility

Verastem Announces Increased Hercules Debt Facility

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced its entry into an amendment to its Loan and Security Agreement with...

Verastem Appoints Joseph Lobacki As Chief Commercial Officer

Verastem Appoints Joseph Lobacki As Chief Commercial Officer

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Joseph Lobacki as Executive Vice President and...

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

First Week Of February 2018 Options Trading For Verastem (VSTM)

First Week Of February 2018 Options Trading For Verastem (VSTM)

Investors in Verastem Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new February 2018 contracts and identified the following put contract of particular interest.

Verastem Announces Pricing Of Public Offering Of Common Stock

Verastem Announces Pricing Of Public Offering Of Common Stock

Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its previously announced underwritten public...

Verastem Announces Public Offering Of Common Stock

Verastem Announces Public Offering Of Common Stock

Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that it intends to offer and sell $25 million of its common stock in...

Verastem Announces The Presentation Of Phase 1 Duvelisib Combination Data In T-Cell Lymphomas At The ASH 2017 Annual Meeting

Verastem Announces The Presentation Of Phase 1 Duvelisib Combination Data In T-Cell Lymphomas At The ASH 2017 Annual Meeting

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of new preclinical and Phase 1 clinical data from...

Verastem Announces Clinical Data From The Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival In Relapsed Or Refractory Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma

Verastem Announces Clinical Data From The Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival In Relapsed Or Refractory Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of the results from the Phase 3 DUO study...

Verastem To Present Results From Pivotal Phase 3 DUO Study In Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At A Research And Development Event At ASH 2017

Verastem To Present Results From Pivotal Phase 3 DUO Study In Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At A Research And Development Event At ASH 2017

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, will present clinical data from the Phase 3 DUO study evaluating the efficacy and...

Verastem To Present At Upcoming Investor Conferences

Verastem To Present At Upcoming Investor Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor...

Verastem Reports Third Quarter 2017 Financial Results

Verastem Reports Third Quarter 2017 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the third quarter ended September 30, 2017 and...

Verastem Announces Data From Phase 3 DUO Study Selected For Oral Presentation At The American Society Of Hematology 2017 Annual Meeting

Verastem Announces Data From Phase 3 DUO Study Selected For Oral Presentation At The American Society Of Hematology 2017 Annual Meeting

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that four abstracts have been selected for presentation, including...

Verastem Announces Regulatory Strategy For Duvelisib New Drug Application Following Guidance From FDA

Verastem Announces Regulatory Strategy For Duvelisib New Drug Application Following Guidance From FDA

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of patients with cancer, today announced that a meeting was held with the U.

Verastem Pays Milestone Payment To Infinity Pharmaceuticals

Verastem Pays Milestone Payment To Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc.

Verastem Appoints NgocDiep Le, MD, PhD As Chief Medical Officer

Verastem Appoints NgocDiep Le, MD, PhD As Chief Medical Officer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of NgocDiep Le, MD, PhD, as Chief Medical Officer.

3 Small Biotech Stocks Insiders Are Buying

3 Small Biotech Stocks Insiders Are Buying

Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.

Verastem To Present At The Cantor Fitzgerald Global Healthcare Conference

Verastem To Present At The Cantor Fitzgerald Global Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25 th at...

First Week Of VSTM November 17th Options Trading

First Week Of VSTM November 17th Options Trading

Investors in Verastem Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Verastem Reaches Analyst Target Price

Verastem Reaches Analyst Target Price

In recent trading, shares of Verastem Inc have crossed above the average analyst 12-month target price of $4.62, changing hands for $4.92/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.